Sai Life Sciences Limited (NSE: SAILIFE, BSE: 544306) is a Hyderabad, Telangana-based company in the Pharmaceutical CDMO and CRO Services industry. With a market capitalisation of ₹40,755 Cr, it ranks #234 by market cap among the 6,197 Indian listed companies on FinBizNet, and #3 of 11 in Pharmaceutical CDMO and CRO Services. At ₹1,927.60 (as of 16 Nov 2026), the share price is 1.4% below its 52-week high of ₹1,954.80 and 145.9% above its 52-week low of ₹783.85. The share price is up 120.3% over one year and up 32.9% over three months.
| Current Price | ₹1,927.60 |
|---|---|
| Market Cap | ₹40,755 Cr |
| NSE Symbol | SAILIFE |
| BSE Code | 544306 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Life Sciences Tools and Services |
| Sub-Industry | Life Sciences Tools and Services > Pharmaceutical CDMO and CRO Services |
| P/E Ratio | 116.1 |
| Return on Equity | 15.13% |
| Return on Assets | 8.57% |
| 52-Week Range | ₹783.85 – ₹1,954.80 |
| 1-Year Price Change | +120.3% |
| 3-Month Price Change | +32.9% |
| Beta (1Y) | 0.21 |
| Headquarters | Hyderabad, Telangana |
| Website | www.sailife.com |
| Revenue | ₹659 Cr |
|---|---|
| Net Profit | ₹98 Cr |
| Net Margin | 14.9% |
| EPS (Basic) | ₹4.63 |
| Basis | consolidated |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
Sai Life Sciences Limited reported revenue of ₹659 Cr in Q2 FY27, up 22.5% from ₹537 Cr in Q2 FY26 and up 18.8% from ₹554 Cr in Q1 FY27. It posted a net profit of ₹98 Cr for the quarter, against a net profit of ₹84 Cr in Q2 FY26 (up 17.3%). Across the 7 quarters from Q4 FY25 to Q2 FY27, quarterly revenue ranged from ₹496 Cr (Q1 FY26) to ₹659 Cr (Q2 FY27). The company was profitable in each of these 7 quarters.
| Quarter | Revenue | Net Profit | Net Margin |
|---|---|---|---|
| Q2 FY27 | ₹659 Cr | ₹98 Cr | 14.9% |
| Q1 FY27 | ₹554 Cr | ₹73 Cr | 13.2% |
| Q4 FY26 | ₹602 Cr | ₹104 Cr | 17.3% |
| Q3 FY26 | ₹556 Cr | ₹100 Cr | 18.0% |
| Q2 FY26 | ₹537 Cr | ₹84 Cr | 15.6% |
| Q1 FY26 | ₹496 Cr | ₹60 Cr | 12.2% |
| Q4 FY25 | ₹580 Cr | ₹88 Cr | 15.2% |
Consolidated figures (₹ crore, XBRL filings).
Promoters held 34.50% of Sai Life Sciences Limited's shares as of Sept 2026, against 34.94% in Sept 2025 (−0.44 percentage points). Delivery averaged 42.6% of traded volume across 16 NSE sessions (22 Oct 2026 – 13 Nov 2026).
Sai Life Sciences Limited operates as a contract research, development, and manufacturing organization (CRDMO) in India and internationally. It provides medicinal chemistry, pharmacokinetics, manufacturing, and contract development services. The company was formerly known as SAI Advantium Pharma Limited and changed its name to Sai Life Sciences Limited in July 2006. Sai Life Sciences Limited was incorporated in 1999 and is based in Hyderabad, India.
1. Contract Research, Development and Manufacturing Services (CRDMO)-This segment provides contract research, development, and manufacturing services. It offers end-to-end services across the drug discovery, development, and manufacturing value chain for small molecule new chemical entities, pharmaceutical companies, and biotechnology firms. 2. NA-NA 3. NA-NA 4. NA-NA
1. Contract Research, Development and Manufacturing Services (CRDMO)-100%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Divis Laboratories Limited | ₹3,01,758 Cr | 118.4 | 16.19% | ₹3,676 Cr | +71.9% |
| Anthem Biosciences Limited | ₹53,926 Cr | 90.1 | 19.45% | ₹594 Cr | +34.5% |
| Sai Life Sciences Limited | ₹40,755 Cr | 116.1 | 15.13% | ₹659 Cr | +120.3% |
| Onesource Specialty Pharma Limited | ₹18,138 Cr | n/m | -1.26% | ₹516 Cr | -9.4% |
| Cohance Lifesciences Ltd | ₹17,756 Cr | 100.6 | 5.11% | ₹477 Cr | -35.2% |
| Syngene International Ltd. | ₹17,630 Cr | 56.9 | 6.62% | ₹833 Cr | -27.9% |
| Jubilant Pharmova Ltd | ₹15,556 Cr | 39.1 | 5.96% | ₹2,370 Cr | -14.5% |
| Concord Biotech Ltd | ₹12,495 Cr | 24.2 | 13.54% | ₹309 Cr | -14.8% |
| Blue Jet Healthcare Ltd | ₹10,140 Cr | 38 | 19.88% | ₹376 Cr | -9.8% |
Listed by market capitalisation. Ratios are shown for context only.
Sai Life Sciences Limited is trading at ₹1,927.60, with a market capitalisation of ₹40,755 Cr.
Sai Life Sciences Limited operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Life Sciences Tools and Services space (Life Sciences Tools and Services > Pharmaceutical CDMO and CRO Services).
Sai Life Sciences Limited has a P/E of 116.1 and a return on equity of 15.13%.
Sai Life Sciences Limited is listed on the NSE under the symbol SAILIFE and on the BSE under the scrip code 544306.
Sai Life Sciences Limited's share price is up 120.3% over one year and up 32.9% over three months. Its 52-week range is ₹783.85 to ₹1,954.80.
In Q2 FY27, Sai Life Sciences Limited reported revenue of ₹659 Cr and net profit of ₹98 Cr, with basic EPS of ₹4.63 (consolidated, parsed from the company's exchange filing).
Sai Life Sciences Limited reported revenue of ₹659 Cr in Q2 FY27, up 22.5% from ₹537 Cr in Q2 FY26 and up 18.8% from ₹554 Cr in Q1 FY27.
Promoters held 34.50% of Sai Life Sciences Limited's shares as of Sept 2026, against 34.94% in Sept 2025 (−0.44 percentage points).
Data as of 16 Nov 2026. Descriptive market data only — not investment advice.